Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis

Annals of the Rheumatic Diseases

Volumn 67, Issue 9, 2008, Pages 1218-1221

  Van Der Heijde, Désirée ^a,j   Pangan, A L ^b   Schiff, M H ^c   Braun, J ^d   Borofsky, M ^e   Torre, J ^f   Davis Jr , J C ^g   Wong, R L ^b   Kupper, H ^h   Collantes, E ⁱ  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ABBOTT LABORATORIES   (United States)

^c CLINICAL RESEARCH UNIT   (United States)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e Clinical Research Center of Reading   (United States)

^f HOSPITAL MONTE NARANCO   (Spain)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h ABBOTT GMBH AND CO KG   (Germany)

ⁱ HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^j NONE   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; PLACEBO;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 50249170430     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.082529     Document Type: Article

References (13)

1. Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol 2006;33(Suppl 78):4-11.
2. Braun J, van der Heijde D, Dougados M, Emery P, Khan MA, Sieper J, et al. Staging of patients with ankylosing spondylitis. Ann Rheum Dis 2002;61(Suppl III):iii19-23.
3. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997;36:766-71.
4. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
5. van der Heijde D, Dijkmans B, Geusens P, Sieper J, De Woody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
6. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
7. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
8. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
9. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
10. van der Heijde D, Dougados M, Davis J, Weisman MH, Maksymowych W, Braun J, et al. Assessments in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum 2005;52:386-94.
11. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
12. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
13. van der Heijde D, Schiff M, Sieper J, Kivitz A, Dijkmans B, Mease P, et al. Adalimumab treatment maintains efficacy and safety in patients with ankylosing spondylitis (AS): 2-year results from ATLAS [Abstract FRI0439], Ann Rheum Dis 2007;66(Suppl II):411-12.